Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 22:9:905728.
doi: 10.3389/fcvm.2022.905728. eCollection 2022.

Comparative analysis of left atrial appendage closure efficacy and outcomes by CHA2DS2-VASc score group in patients with non-valvular atrial fibrillation

Mingzhong Zhao  1   2 , Mengxi Zhao  3 , Cody R Hou  4 , Felix Post  5 , Nora Herold  5 , Jens Walsleben  5 , Qingru Yuan  1 , Zhaohui Meng  2   6 , Jiangtao Yu  2   5
Affiliations

Comparative analysis of left atrial appendage closure efficacy and outcomes by CHA2DS2-VASc score group in patients with non-valvular atrial fibrillation

Mingzhong Zhao et al. Front Cardiovasc Med. .

Abstract

Background: Higher CHA2DS2-VASc score is associated with an increased risk of adverse cardio-cerebrovascular events in patients with non-valvular atrial fibrillation (NVAF), regardless of oral anticoagulation (OAC) status. However, whether this association still exists in patients undergoing left atrial appendage closure (LAAC) is unknown. We evaluated the impact of CHA2DS2-VASc score on LAAC efficacy and outcomes.

Methods: A total of 401 consecutive patients undergoing LAAC were included and divided into 3 groups based on CHA2DS2-VASc score (0-2, 3-4, and ≥5). Baseline characteristics, periprocedural complications, and long-term outcomes were collected and compared across all groups.

Results: There were no significant differences in implantation success, periprocedural complications, and long-term outcomes across all score groups. Kaplan-Meier estimation showed that the cumulative ratio of freedom from all-cause mortality (P = 0.146), cardiovascular mortality (P = 0.519), and non-cardiovascular mortality (P = 0.168) did not differ significantly by CHA2DS2-VASc score group. LAAC decreased the risks of thromboembolism and major bleeding, resulting in a relative risk reduction (RRR) of 82.4% (P < 0.001) and 66.7% (P < 0.001) compared with expected risks in the overall cohort, respectively. Subgroup analysis indicated that observed risks of thromboembolism and major bleeding were significantly lower than the expected risks in score 3-4 and score ≥5 groups, respectively. The level of RRR increased with CHA2DS2-VASc score (P < 0.001 for trend) for thromboembolism but not for major bleeding (P = 0.2729 for trend).

Conclusion: Patients with higher CHA2DS2-VASc score did not experience worse outcomes, which may be partly attributed to more benefits provided by LAAC intervention in such patients compared to those with a low score.

Keywords: CHA2DS2-VASc score; atrial fibrillation; left atrial appendage closure; major bleeding; outcomes; stroke.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Comparison of the cumulative ratio of freedom from all-cause mortality in different subgroups. LAAC, left atrial appendage closure.
Figure 2
Figure 2
Comparison of the cumulative ratio of freedom from cardiovascular mortality in different subgroups. LAAC, left atrial appendage closure.
Figure 3
Figure 3
Comparison of the cumulative ratio of freedom from non-cardiovascular mortality in different subgroups. LAAC, left atrial appendage closure.
Figure 4
Figure 4
Effectiveness of LAAC in risk reduction of thromboembolism (100 patient-years) during the follow-up in the study groups divided according to CHA2DS2-VASc score. RRR, relative risk reduction.
Figure 5
Figure 5
Effectiveness of LAAC in risk reduction of major bleeding (100 patient-years) during the follow-up in the study groups divided according to CHA2DS2-VASc score. RRR, relative risk reduction.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Lloyd-Jones DM, Wang TJ, Leip EP. Lifetime risk for development of atrial fibrillation: the Framingham heart study. Circulation. (2004) 110:1042–6. 10.1161/01.CIR.0000140263.20897.42 - DOI - PubMed
    1. Bosch NA, Cimini J, Walkey AJ. Atrial fibrillation in the ICU. Chest. (2018) 154:1424–34. 10.1016/j.chest.2018.03.040 - DOI - PMC - PubMed
    1. Själander S, Sjögren V, Renlund H, Norrving B, Själander A. TDabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. Thromb Res. (2018) 167:113–18. 10.1016/j.thromres.2018.05.022 - DOI - PubMed
    1. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. . Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. (2014) 383:955–62. 10.1016/S0140-6736(13)62343-0 - DOI - PubMed
    1. Marsico F, Cecere M, Parente A, Paolillo S, de Martino F, Dellegrottaglie S, et al. . Effects of novel oral anticoagulants on left atrial and left atrial appendage thrombi: an appraisal. J Thromb Thrombolysis. (2017) 43:139–48. 10.1007/s11239-016-1421-9 - DOI - PubMed

LinkOut - more resources